Billions Lost at BioNTech, TeamViewer Hopes for a Turnaround, and Lahontan Gold Poised for a Breakout?

BioNTech: The Painful Road Back to Reality

BioNTech was once the undisputed shining star in the German stock market sky when the COVID-19 crisis dominated daily trading. But the harsh reality of the post-COVID era has caught up with the Mainz-based company. For many observers, the figures for the just-concluded second quarter do not look all that great. The company posted a hefty net loss of EUR 820.8 million. As a result, the executive board felt compelled to slash its ambitious revenue forecast for the current full year to between EUR 1.6 and 1.9 billion. Previously, executives had been dreaming of revenues well beyond the EUR 2 billion mark. The painful consequence of this development is now evident in a nearly ruthless restructuring plan.

Up to 1,860 jobs are set to be cut across the group. Key locations such as Marburg, Tübingen, and Singapore are facing a drastic scaling back of production. But the real drama is unfolding not only there, but also at the top management level. The once globally celebrated founding couple, Ugur Sahin and Özlem Türeci, will leave the company by the end of 2026. The news came as a shock! Starting in February 2027, Guido Oelkers is set to take the helm and steer the company through this period of upheaval. With the share price currently hovering stubbornly around USD 90–92 (EUR 77–79), the stock remains well below last year's level.

Nevertheless, BioNTech is far from being written off, as its war chest is brimming with around EUR 16.6 billion. This financial cushion gives the company the much-needed time to advance its numerous ongoing Phase 3 oncology trials calmly. A first ray of hope could be an upcoming milestone payment from a collaboration, which would provide the much-needed positive momentum. However, it remains a tough game of playing for time, one that is likely to continue to strain the nerves of shareholders to the limit.

From the laboratories in Mainz, we now turn to the digital world of remote maintenance with TeamViewer. Our second company is also facing challenging conditions, but in this case the signs point to a very different kind of transformation.

TeamViewer: Undergoing a Transformation with a Glimmer of Hope

For several months, the stock of the Göppingen-based software specialist TeamViewer resembled a funeral procession. But then a turnaround began at just over EUR 4. Following the latest quarterly figures, however, there was another setback. The share price slipped by nearly 10% at one point but is currently trading higher again in the range of just over EUR 6.55. Many short-term investors initially reacted with visible disappointment to the rather subdued revenue growth. But a closer look behind the scenes reveals that TeamViewer is intensively restructuring its traditional business model and is now focusing more strongly on lucrative and loyal large corporate clients.

The widespread rollout of the new TeamViewer ONE platform is considered an absolutely central component of the future strategy. Industry experts view the launch of this platform as evidence that the strategic realignment is gradually beginning to take hold. Analysts remain relatively optimistic despite the short-term share price turbulence. For example, a well-known bank recently raised its price target to EUR 9 and issued a "Buy" recommendation. Financial experts are already seeing early signs that key recurring revenue in the enterprise segment could soon accelerate noticeably.

TeamViewer is undoubtedly at a crossroads. The far-reaching restructuring requires patience from investors, but the long-term prospects for a sustainable comeback remain intact. However, the coming quarters will have to reveal whether the analysts' newfound confidence is actually justified. From a technical analysis perspective, the share could move toward EUR 8, as that is where the sharp sell-off began last year. Such moves are usually corrected later on.

While BioNTech and TeamViewer are grappling with the shadows of the past and arduous restructuring efforts, our attention now turns to Nevada—more specifically, to Lahontan Gold.

Lahontan Gold: "Desert Gold" with Technical Breakout Potential

The exploration company is pushing forward with the development of its flagship project, the Santa Fe Mine in Nevada. The share price has been on a truly wild ride in recent months. After a spectacular rise from a modest CAD 0.10 in August 2025, the stock soared to a peak of CAD 0.52 in March 2026. A true dream come true for early investors. Since then, this massive rise has been gradually corrected within a classic wedge pattern. The current share price has settled at around CAD 0.33.

From a technical analysis perspective, however, things are getting extremely exciting right now. If the critical range of CAD 0.38 to 0.39 is breached, the breakout would be nothing short of impressive. The stock could then rise again with completely new momentum, heading straight back toward the previous high of CAD 0.52. Furthermore, the chart even shows nearly unlimited upside potential up to a price range of CAD 0.75 to 0.80. On the downside, the stock is well supported by a horizontal support line within the Buy zone.

But it is not just the chart that may be signaling more—fundamental developments also provide strong arguments. Management recently announced that it is fully on schedule to begin actual construction of the mine in 2027. To date this year, 87 drill holes have already been successfully and safely completed. In particular, the recent discovery of the new Slab West zone, which remains open in all directions, is fueling investor imagination. The eagerly anticipated updated resource estimate, as well as a revised preliminary economic assessment (PEA), are now expected to be released soon.

In addition, the company delivered strong follow-up results from further drilling. From the Calvada Central area, the company reported a top hit of just under 31 m grading 0.93 g/t gold. What is truly remarkable is that this particular drill hole was intended only to collect basic geotechnical data. However, it penetrated the core of the deposit with pinpoint accuracy.

Shortly thereafter, Lahontan surprised the markets once again when, during a targeted investigation of a historic tailings pile, it encountered unexpectedly high grades of 2.40 g/t gold and over 50 g/t silver over nearly 10 m. These old tailings piles, where millions of metric tons of rock are piled up, could soon prove to be an extremely lucrative and cost-effective source of future revenue. Management is demonstrating an astonishingly good knack for efficiently unlocking long-forgotten value.

We have taken a closer look at three very different companies, each facing its own unique set of opportunities and challenges. BioNTech is undergoing a historic transition. The departure of its founding leaders and declining revenues demand patience and resilience from investors, although the company's substantial cash reserves continue to provide an important financial cushion.

TeamViewer, meanwhile, is seeking to emerge from its period of weakness by focusing on high-value enterprise customers. Analysts are becoming increasingly optimistic, but the company still needs to demonstrate that it can deliver sustainable long-term growth.

Among the three, Lahontan Gold stands out as the most compelling growth story. Its technical chart setup appears attractive for investors with a higher risk tolerance, while the company's operational progress at its Nevada projects continues to strengthen the investment case. For those seeking exposure to a well-managed gold developer with strong momentum and meaningful downside support, Lahontan Gold represents an attractive portfolio addition.